Developing Oral Dosage Forms: An Agnostic and Data-driven Approach for Faster Path to Market
Summary: With the emphasis on developing treatments for complex diseases, the nature of the molecules in the global pharmaceutical pipeline is changing and formulating an oral dose has become more challenging. An agnostic and data-driven approach early on enables formulation scientists to screen formulations and find a technology with optimal bioavailability suitable for animal studies and to enable further development of clinical trial materials. Learn about the approach for Fast Path to Phase I.